Cat allergy (disorder)

QUEBEC CITY--(BUSINESS WIRE)-- ANGANY inc. announces the completion on schedule of its first clinical trial, assessing the safety and allergenicity of its therapeutic candidate against human allergy to cats. The study results were consistent throughout the 20 human adult cat allergic participants. The final results and conclusions of this clinical trial will be submitted to a major scientific journal. Skillfully conducted and on-time ANGANY’s First-in-Human study of its novel biologic ANG-101 candidate vaccine against cat allergy concluded in December 2023, ahead of schedule. The enthusiasm for a novel solution for cat allergy facilitated enrollment. The skills and professional expertise of Dr. Guy Scadding and Pr. Stephen Durham, the study investigators, were central in conducting this open-label clinical study safely and swiftly. ANGANY is now able to move further ahead with the preparation of its next phase study of the same asset. Favorable results Preliminary accounts showed consistency in the results and an excellent safety profile. ANG-101 was associated with significant hypoallergenicity, a marker of safety and long sought-after feature in allergy therapeutics, when compared to a commercial cat dander extract. Important publication Detailed results and conclusions of the study will be submitted to a top-tier scientific journal for publication. The results should also be presented at the EAACI’s Annual Meeting to be held in Valencia in May 2024. Quotes “We are very pleased with the rapid completion and results of this First-in-Human study. The demonstrated safety and hypoallergenicity of ANG-101 represent the cornerstone of the further clinical development of this breakthrough technology,” stated Patrick Colin, BPharm, PhD, ANGANY’s vice-president of clinical development. We are delighted to report on a significant step forward in the company’s development. This milestone couldn’t have been reached without the expertise of our investigators, the participants’ commitment, and the dedication of our team. I would like to extend my warm thanks to all,” stated Christine Guillen, CEO of ANGANY. About ANGANY ANGANY is a Franco-Canadian private clinical-stage biotech company pioneering a new immunotherapy approach to overcome the challenge of allergy. ANGANY’s eBioparticle™ technology makes for biologics of a new generation to be administered as vaccines. ANGANY's eBioparticle-Potentiated Immunotherapy™ also opens-up new prospects in fields of application beyond allergy in human and animal health, notably in cancer immunotherapy. Read the full press release: View source version on businesswire.com: Contacts Investors Relations: Guy Tropper MD Executive Vice-President guy.tropper@angany.com Source: ANGANY inc. View this news release online at:

ANGANY expands and redefines its executive team to better manage upcoming development stages. QUEBEC CITY--(BUSINESS WIRE)-- ANGANY announces the appointment of Christine Guillen, PharmD, as Chief Executive Officer. In this capacity, Ms. Guillen will sit on the Board of Directors. ANGANY also announces the strengthening of its Executive Committee with the appointment of Mr. Patrick Colin, BPharm PhD, as Vice-President, Clinical Development, and Pr. Claude Favrot, DMV, as Vice-President, Veterinary Development. A pharmacist by training, Ms. Guillen brings with her a solid expertise in biopharmaceuticals, as well as extensive experience in managing innovative life sciences companies. She joins the ANGANY team as the company reaches a turning point. With the start of clinical development of its next-generation biologic ANG-101 for the treatment of cat allergy, ANGANY must evolve its programs and operations. Ms. Guillen's structured approach will accelerate the achievement of value milestones on ANGANY’s timetable. Ms. Guillen says: "I'm delighted to take up the challenge of bringing a breakthrough technology to a tangible clinical and pharmaceutical reality. We are privileged to have been able to recruit Patrick Colin and Claude Favrot, each an authority in his field through their respective competence and experience." Former CEO Louis-Philippe Vézina was instrumental in recruiting his successor. He has been appointed Executive Chairman of the Board. About ANGANY ANGANY is a Franco-Canadian private clinical-stage biotech company pioneering a new immunotherapy approach to overcome the challenge of allergy through breakthrough therapeutics. ANGANY’s eBioparticle™ technology makes for biologics of a new generation to be administered as vaccines. The goal is to restore or reinforce natural immune mechanisms and create lasting immune protection. ANGANY's eBioparticle-Potentiated Immunotherapy™ also opens-up new prospects in several fields of application beyond allergy in human and animal health, notably in cancer immunotherapy. The company operates a cGMP pilot production unit in Quebec, as well as an R&D laboratory in France. ANGANY uses a flexible, efficient and easily scalable 3rd generation plant bioproduction platform to manufacture its next-generation biologics. For more information: ANGANY View source version on businesswire.com: Contacts Medias and investor relations: Guy Tropper MD FRCSC Co-Founder and Executive Vice-President guy.tropper@angany.com Source: ANGANY View this news release online at:

[05-October-2023] The Royal Brompton Hospital, in London, begins Clinical Trial of Angany's Vaccine Candidate to treat Cat Allergy. QUEBEC CITY, Oct. 5, 2023 /CNW/ - Angany Inc., announces that it has received clearance (Notice of Acceptance) from MHRA (Medicines and Healthcare Products Regulatory Agency) for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats. This clinical study is a First in Human, open label and single site evaluation of the safety, allergenicity and immunogenicity of the new vaccine in adult patients allergic to cat dander and will be conducted under the guidance of Professor Stephen Durham and Dr Guy Scadding, two leading clinical allergy experts from Imperial College London. A promising approach against cat allergy There is currently no cure for cat allergy, which is a very common and life-long condition. Over-the-counter and prescription medications relieve patients of symptoms, but do not prevent allergy from progressing. The only disease-modifying treatment against allergy is desensitization, a form of allergen immunotherapy, which requires years of cat allergen administration and is associated with a poor success rate and the risk of allergic side effects. Angany's ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for the treatment of cat allergy. Derived from its proprietary eBioparticle-Potentiated Immunotherapy™ technology, ANG-101 active immunotherapeutic ingredient is a unique 140 nm enveloped bioparticle (eBioparticle™) that mimics a virus in shape and size with its surface covered with thousands of copies of cat major allergen Fel d 1. Quotes "We are very pleased that our new and promising approach to cat allergy immunotherapy is now being tested in patients, in a study that constitutes the first step of a comprehensive clinical development program. We have named this clinical study "HOPE" as this important milestone in Angany's vaccine development program should raise new hope for millions of people affected by allergy worldwide. ANG-101 is a first from a vaccine portfolio in development that aims to cover major allergies in humans and companion animals." — Dr Louis-Philippe Vézina, President and CEO of Angany and a successful pharmaceutical entrepreneur, world-renowned for his expertise in the design and production of new generations of vaccines "The potential treatment of cat allergy using an auto-adjuvanted vector builds upon its known ability to induce strong allergen-specific IgG antibody responses, as observed in animal models." — Professor Stephen Durham, Head of Section for Allergy and Clinical Immunology at NHLI, Imperial College and Professor of Allergy and Respiratory Medicine at Royal Brompton Hospital London "The ultimate goal in cat allergy is to find a safe, effective and easy to administer vaccine that will not require the long treatment and often suboptimal response currently featured by classical desensitization method." — Dr. Guy Scadding, clinical research fellow at the National Heart and Lung Institute of the Imperial College London About Angany Founded in 2017 and based in Quebec City, Canada, Angany is a clinical stage, private Frenco-Canadian pharmaceutical company dedicated to fighting allergies with a novel approach to immunotherapy. The company is pursuing the development of therapeutic vaccines for the treatment of allergies, a mission initiated in France, and recently, in the oncology field in partnership with CHUM Research Center (Montreal). Angany uses a flexible, fast and easily scalable 3rd generation plant-based bioproduction platform for the manufacturing of its eBP-based vaccines. Angany anticipates that its eBioparticle vaccinal platform will rapidly find direct applications in domains other than allergy, namely in cancer immunotherapy and in the treatment of autoimmune diseases. Since the beginning of its research work, Angany has benefited from the financial support of the Quebec government. About eBioparticle™ and eBioparticle-Potentiated Immunotherapy™ technology Unlike common prophylactic vaccines (preventive), Angany's first-in-Class therapeutic vaccines are a new generation of immunotherapy biologics that are used to treat established pathologies. They are meant to restore or boost natural immune mechanisms and create sustainable immune protection and vigilance. For more information, visit com. SOURCE Angany inc.